Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Maintains Buy on Gemini Therapeutics, Lowers Price Target to $18

Goldman Sachs analyst Graig Suvannavejh maintains Gemini Therapeutics (NASDAQ:GMTX) with a Buy and lowers the price target from $20 to $18.
byBenzinga Newsdesk
October 6, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Graig Suvannavejh maintains Gemini Therapeutics (NASDAQ:GMTX) with a Buy and lowers the price target from $20 to $18.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts